CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Michael McDonald,Sean A. Virani,Michael Chan,Anique Ducharme,Justin A. Ezekowitz,Nadia Giannetti,George A. Heckman,Jonathan G. Howlett,Sheri L. Koshman,Serge Lepage,Lisa Mielniczuk,Gordon W. Moe,Eileen O'Meara,Elizabeth Swiggum,Mustafa Toma,Shelley Zieroth,Kim Anderson,Sharon A Bray,Brian Clarke,Alain Cohen-Solal,Michel D'Astous,Margot K. Davis,Sabe De,Andrew Grant,Adam Grzeslo,Jodi Heshka,Sabina L.C. Keen,Simon Kouz,Douglas S. Lee,Frederick A. Masoudi,Robert S. McKelvie,Marie-Claude Parent,Stephanie Poon,Miroslaw Rajda,Abhinav Sharma,Kyla Siatecki,Kate Storm,Bruce Sussex,Harriette G.C. Van Spall,Amelia Ming Ching Yip +39 more
Reads0
Chats0
TLDR
In this paper, the authors provide comprehensive recommendations and practical tips for the pharmacologic management of patients with heart failure with reduced ejection fraction (HFrEF) including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators.About:
This article is published in Canadian Journal of Cardiology.The article was published on 2021-04-01 and is currently open access. It has received 137 citations till now.read more
Citations
More filters
Journal ArticleDOI
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial
TL;DR: The study of Dietary Intervention under 100 mmol in Heart Failure (SODIUM-HF) as mentioned in this paper was designed to test whether or not a reduction in dietary sodium reduces the incidence of future clinical events.
Journal ArticleDOI
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
TL;DR: In this article , the authors proposed that SGLT2 inhibitors are generally safe and well tolerated, with clinical trial data reporting minimal effects on blood pressure, glycaemia-related adverse events, and no excess in acute kidney injury.
Journal ArticleDOI
Optimizing Foundational Therapies in Patients With HFrEF
Abhinav Sharma,Subodh Verma,Deepak L. Bhatt,Kim A. Connelly,Elizabeth Swiggum,Muthiah Vaduganathan,Shelley Zieroth,Javed Butler +7 more
TL;DR: In this article , the authors proposed a guideline-directed medical therapy (GDMT) that can reduce the risk of morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF).
Journal ArticleDOI
A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction.
TL;DR: In this paper, the authors discuss mechanisms of action of these therapies and propose a framework for their implementation, based on several principles, including the critical importance of rapid initiation of all 4 Foundational Therapies followed by their titration to target doses, emphasis on multiple simultaneous drug changes with each patient encounter, attention to patient-specific factors in choice of medication class, leveraging inpatient care, use of the entire health care team, and alternative (ie, virtual visits) modes of care.
Journal ArticleDOI
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu,Vikas S. Sridhar,Jacinthe Boulet,Atit Dharia,Abid Khan,Patrick R. Lawler,David Z.I. Cherney +6 more
TL;DR: In this paper, the authors highlight biomarkers linked with diabetic kidney disease and heart failure and discuss how SGLT2 inhibitor-associated changes potentially mediate the cardiorenal protection observed with these therapies.
References
More filters
Journal ArticleDOI
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
Journal ArticleDOI
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Abstr Act +11 more
TL;DR: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
TL;DR: Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
Related Papers (5)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer,S. D. Anker,J. Butler,G. Filippatos,S. J. Pocock,P. Carson,James L. Januzzi,S. Verma,H. Tsutsui,M. Brueckmann,W. Jamal,K. Kimura,J. Schnee,C. Zeller,D. Cotton,Edimar Alcides Bocchi,M. Böhm,Dong-Ju Choi,V. Chopra,E. Chuquiure,N. Giannetti,S. Janssens,J. Zhang,J. R. Gonzalez Juanatey,Sanjay Kaul,H. P. Brunner-La Rocca,Béla Merkely,Stephen J. Nicholls,Sergio V. Perrone,I. Pina,P. Ponikowski,N. Sattar,Michele Senni,M. F. Seronde,J. Spinar,Iain B. Squire,S. Taddei,Christoph Wanner,F. Zannad +38 more
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer,Gerasimos Filippatos,John J.V. McMurray,Victor Aboyans,Stephan Achenbach,Stefan Agewall,Nawwar Al-Attar,John Atherton,Johann Bauersachs,A. John Camm,Scipione Carerj,Claudio Ceconi,Antonio Coca,Perry M. Elliott,Çetin Erol,Justin A. Ezekowitz,Covadonga Fernández-Golfín,Donna Fitzsimons,Marco Guazzi,Maxime Guenoun,Gerd Hasenfuss,Gerhard Hindricks,Arno W. Hoes,Bernard Iung,Tiny Jaarsma,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Stavros Konstantinides,Mitja Lainscak,Patrizio Lancellotti,Gregory Y.H. Lip,Francesco Maisano,Christian Mueller,Mark C. Petrie,Massimo F Piepoli,Silvia G. Priori,Adam Torbicki,Hiroyuki Tsutsui,Dirk J. van Veldhuisen,Stephan Windecker,Clyde W. Yancy,José Luis Zamorano +62 more
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt,Michael Szarek,P. Gabriel Steg,Christopher P. Cannon,Lawrence A. Leiter,Darren K. McGuire,Julia B. Lewis,Matthew C. Riddle,Adriaan A. Voors,Marco Metra,Lars H. Lund,Michel Komajda,Jeffrey M. Testani,Christopher S. Wilcox,Piotr Ponikowski,Renato D. Lopes,Subodh Verma,Pablo Lapuerta,Bertram Pitt +18 more
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Monica Colvin,Mark H. Drazner,Gerasimos Filippatos,Gregg C. Fonarow,Michael M. Givertz,Steven M. Hollenberg,JoAnn Lindenfeld,Frederick A. Masoudi,Patrick E. McBride,Pamela N. Peterson,Lynne W. Stevenson,Cheryl Westlake +16 more